Skip to main content

Bisphosphonates in the treatment of osteoporosis


Bisphosphonates are compounds derived from pyrophosphate, a byproduct of cellular cleavage of adenosine triphosphate (ATP), and are resistant to alkaline phosphatase by virtue of replacement of oxygen by carbon. The high affinity of the P-C-P structure for hydroxyapatite accounts for deposition in bone. Modification of the two side chains of carbon alters the potency of the drugs. Of those that have either completed or are undergoing clinical trials, the order of increasing potency for inhibition of bone resorption is etidronate, clodronate, tiludronate, pamidronate, alendronate, residronate and ibandronate (potency range: 1 to 10,000). Less than 5% of bisphosphonates are absorbed and the half life is a few hours. The drugs must be given on an empty stomach because food and beverages interfere with gastrointestinal absorption. Of the absorbed fraction, as much as 60% is taken up by the skeleton and the remainder is excreted un changed in the urine. Etidronate, tiludronate, residronate, and alendronate are given orally, clodronate intravenously, and pamidronate and ibandronate by either route. At lower concentrations, bisphosphonates inhibit osteoclatic bone resorption, whereas at higher concentrations they may inhibit mineralization and cause osteomalacia. Inhibition of mineralization diminishes with increasing potency. In postmenopausal women, etidronate and alendronate for 3 yr were shown to inhibit bone resorption, increase bone mineral density (BMD) of the lumbar spine and hip, and prevent fractures without producing osteomalacia. Bone formation also is reduced as a consequence of diminished bone resorption but reduction is less than the reduction of bone resorption. In higher doses bisphosphonates may cause upper gastrointestinal disturbances but in recommended doses they generally are well tolerated and have an excellent safety profile.

This is a preview of subscription content, access via your institution.


  1. Fleisch, H. (1981).Metab. Bone. Dis. Rel. Res. 4, 279–288.

    Article  Google Scholar 

  2. Fleisch, H. (1995). InBisphosphonates in Bone Disease: from the Laboratory to the Patient. 2nd. ed. The Parthenon Publishing Group: New York.

    Google Scholar 

  3. Fleisch, H. (1991).Drugs 42, 919–944.

    PubMed  CAS  Google Scholar 

  4. DeGroen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., and Wang, K. K. (1996).N. Engl. J. Med. 335, 1018–1021.

    Article  Google Scholar 

  5. Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., and Martin, T. J. (1993).J. Clin. Invest. 91, 2004–2011.

    Article  PubMed  CAS  Google Scholar 

  6. Green, J. R., Muller, K., and Jaeggi, K. A. (1994).J. Bone Miner. Res. 9, 745–751.

    PubMed  CAS  Google Scholar 

  7. Mühlbauer, R. C. (1994). InSex Steroids and Bone. Ziegler, R., Pfeilschifter, J., and Bräutigam, M. (eds.). Springer-Verlag: Heidelberg, pp. 191–202.

    Google Scholar 

  8. Chesnut, C. H., III, McClung, M. R., Ensrud K. E., Bell, N. H., Genant, K., Harris, S. T., Singer, F. R., Stock, J. L., Yood, R. I., Delmas, P. D., Kher, U., Pryor-Tillotson, S., and Santora, A. C., II. (1995).Am. J. Med. 99, 144–152.

    Article  PubMed  CAS  Google Scholar 

  9. Liberman, U. A., Weiss, S. R., Broll, J. H., Rodriguez-Portalis, J., Downs, R. W., Seeman, E., Recker, R. R., Capizzi, T., Santora, A., II, and Lombardi, A., Shah, R. V., Hirsch, J. H., and Karpf, D. B. (1995).N. Engl. J. Med. 333, 1437–1443.

    Article  PubMed  CAS  Google Scholar 

  10. Giannini, S., D’Angelo, A., Malvasi, L., Castrignano, R., Pati, T., Tronca, R., Liberto, L., Nobile, M., and Crepaldi, G. (1993).Bone 14, 137–141.

    Article  PubMed  CAS  Google Scholar 

  11. Harris, S. T., Watts, N. B., Jackson, R. D., Genant, H. K., Wasnich, R. D., Ross, P., Miller, P. D., Licata, A. A., and Chesnut, C. H., III. (1993).Am. J. Med. 95, 557–567.

    Article  PubMed  CAS  Google Scholar 

  12. Reid, I. R., Watti, D. J., Evans, M. C., Gamble, G. D., Stapleton, J. P., and Cornish, J. (1994).J. Clin. Endocrinol. Metab. 79, 1595–1599.

    Article  PubMed  CAS  Google Scholar 

  13. Thiebaud, D., Burckhartd, P., Melchior, J., Eckert, P., Jacquet, A. F., Schnyder, P., and Gobelet, C. (1994).Osteoporosis Int. 4, 76–83.

    Article  CAS  Google Scholar 

  14. Landman, J. O., Hamdy, N. A. T., Pauwels, E. K. J., and Papapoulos, S. E. (1995).J. Clin. Endocrinol. Metab. 80, 3465–3468.

    Article  PubMed  CAS  Google Scholar 

  15. Reginster, J. Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., and Franchimont, P. (1989).Lancet 2, 1469–1471.

    Article  PubMed  CAS  Google Scholar 

  16. Thompson, D. D., Seedor, J. G., Quartuccio, H., Solomon, H., Fioravanti, C., David, J., Klein, H., Jackson, R., Clair, J., Frankenfield, D., Brown, E., Simmons, H. A., and Rodan, G. A. (1992).J. Bone Miner. Res. 7, 951–960.

    Article  PubMed  CAS  Google Scholar 

  17. Toolan, B. C., Shea, M., Myers, E. R., Borchers, R. E., Seedor, J. G., Quartuccio, H., Rodan, G. A., and Hayes, W. C. (1993).J. Bone Miner. Res. 7, 1399–1406.

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bell, N.H., Johnson, R.H. Bisphosphonates in the treatment of osteoporosis. Endocr 6, 203–206 (1997).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:

Key Words